CA2478423A1 - Gamma secretase inhibitors - Google Patents

Gamma secretase inhibitors Download PDF

Info

Publication number
CA2478423A1
CA2478423A1 CA002478423A CA2478423A CA2478423A1 CA 2478423 A1 CA2478423 A1 CA 2478423A1 CA 002478423 A CA002478423 A CA 002478423A CA 2478423 A CA2478423 A CA 2478423A CA 2478423 A1 CA2478423 A1 CA 2478423A1
Authority
CA
Canada
Prior art keywords
alkyl
substituted
group
unsubstituted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002478423A
Other languages
English (en)
French (fr)
Inventor
Dmitri A. Pissarnitski
Hubert B. Josien
Elizabeth M. Smith
John W. Clader
Theodros Asberom
Tao Guo
Douglas W. Hobbs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2478423A1 publication Critical patent/CA2478423A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
CA002478423A 2002-02-06 2003-02-05 Gamma secretase inhibitors Abandoned CA2478423A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35561802P 2002-02-06 2002-02-06
US60/355,618 2002-02-06
PCT/US2003/003471 WO2003066592A1 (en) 2002-02-06 2003-02-05 Gamma secretase inhibitors

Publications (1)

Publication Number Publication Date
CA2478423A1 true CA2478423A1 (en) 2003-08-14

Family

ID=27734543

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002478423A Abandoned CA2478423A1 (en) 2002-02-06 2003-02-05 Gamma secretase inhibitors

Country Status (21)

Country Link
US (2) US7208602B2 (https=)
EP (1) EP1472223A1 (https=)
JP (1) JP4758609B2 (https=)
KR (1) KR20040081489A (https=)
CN (1) CN1628100A (https=)
AR (1) AR038482A1 (https=)
AU (1) AU2003210865B2 (https=)
BR (1) BR0307492A (https=)
CA (1) CA2478423A1 (https=)
CO (1) CO5611195A2 (https=)
EC (1) ECSP045218A (https=)
MX (1) MXPA04007659A (https=)
MY (1) MY141504A (https=)
NO (1) NO329067B1 (https=)
NZ (1) NZ534223A (https=)
PE (1) PE20030977A1 (https=)
PL (1) PL371735A1 (https=)
RU (1) RU2004126864A (https=)
TW (1) TW200302717A (https=)
WO (1) WO2003066592A1 (https=)
ZA (1) ZA200406237B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100562516C (zh) 2001-12-27 2009-11-25 第一制药株式会社 β-淀粉样蛋白产生和分泌的抑制剂
US20040171614A1 (en) * 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
US7256186B2 (en) 2002-02-06 2007-08-14 Schering Corporation Gamma secretase inhibitors
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2004080966A1 (ja) 2003-03-14 2004-09-23 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
CA2526487A1 (en) 2003-06-30 2005-01-06 Daiichi Pharmaceutical Co., Ltd. Heterocyclic methyl sulfone derivative
MXPA06001558A (es) 2003-08-08 2006-05-15 Schering Corp Inhibidores de amina ciclica bace-1 que poseen un sustituyente heterociclico.
ES2323068T3 (es) 2003-08-08 2009-07-06 Schering Corporation Inhibidores de bace-1 de aminas ciclicas con un sustituyente de benzamida.
RU2364587C2 (ru) * 2003-10-29 2009-08-20 Элан Фармасьютикалз, Инк. N-замещенные бензолсульфонамиды
TWI300410B (en) * 2004-04-05 2008-09-01 Schering Corp Novel gamma secretase inhibitors
CA2567343A1 (en) * 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
PE20060481A1 (es) * 2004-06-30 2006-06-19 Schering Corp N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas
KR100880972B1 (ko) * 2004-07-13 2009-02-03 에프. 호프만-라 로슈 아게 설폰아마이드 유도체
EP1781625B1 (en) 2004-07-22 2010-12-15 Schering Corporation Substituted amide beta secretase inhibitors
EP1790637B1 (en) 2004-09-13 2014-01-29 Ono Pharmaceutical Co., Ltd. Derivatives of N-4-piperidyl urea and medicaments containing them as active ingredient
GB0423356D0 (en) * 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
BRPI0614944A2 (pt) * 2005-08-19 2011-04-26 Elan Pharm Inc inibidores sulfonamido n-bicìclicos ponte de gama-secretase
KR20090008217A (ko) 2006-03-10 2009-01-21 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제
ATE509956T1 (de) * 2006-06-08 2011-06-15 Helmholtz Zentrum Muenchen Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie
EP2383267A1 (de) * 2006-09-29 2011-11-02 Grünenthal GmbH Substituierte Sulfonamid-Derivate
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
CA2669917A1 (en) * 2006-11-17 2008-05-22 Dawn M. George Aminopyrrolidines as chemokine receptor antagonists
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
JP2010528036A (ja) * 2007-05-25 2010-08-19 エラン ファーマシューティカルズ，インコーポレイテッド γセクレターゼの阻害剤としてのピラゾロピロリジン
JP2011523655A (ja) * 2008-06-03 2011-08-18 フレセニウス メディカル ケア ドイッチュランド ゲーエムベーハー ガンマセクレターゼモジュレータを含む医薬組成物
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687146B1 (fr) * 1992-02-12 1994-04-01 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US6166037A (en) * 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
GB9800750D0 (en) * 1998-01-14 1998-03-11 Lilly Co Eli Pharmaceutical compound
GB9804426D0 (en) * 1998-03-02 1998-04-29 Pfizer Ltd Heterocycles
TW575561B (en) * 1999-03-25 2004-02-11 Hoffmann La Roche 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives

Also Published As

Publication number Publication date
MY141504A (en) 2010-05-14
AR038482A1 (es) 2005-01-19
RU2004126864A (ru) 2005-07-10
KR20040081489A (ko) 2004-09-21
BR0307492A (pt) 2004-11-23
ZA200406237B (en) 2005-09-22
PE20030977A1 (es) 2003-12-04
AU2003210865B2 (en) 2008-01-31
TW200302717A (en) 2003-08-16
US20040048848A1 (en) 2004-03-11
MXPA04007659A (es) 2005-06-08
CO5611195A2 (es) 2006-02-28
PL371735A1 (en) 2005-06-27
WO2003066592A1 (en) 2003-08-14
CN1628100A (zh) 2005-06-15
JP4758609B2 (ja) 2011-08-31
NZ534223A (en) 2007-05-31
EP1472223A1 (en) 2004-11-03
US20060100427A1 (en) 2006-05-11
JP2005522437A (ja) 2005-07-28
ECSP045218A (es) 2004-09-28
US7208602B2 (en) 2007-04-24
NO20043696L (no) 2004-11-05
AU2003210865A1 (en) 2003-09-02
NO329067B1 (no) 2010-08-16

Similar Documents

Publication Publication Date Title
CA2478423A1 (en) Gamma secretase inhibitors
EP3481828B1 (en) Spiro-fused cyclic ureas as inhibitors of rock
CA2455863C (en) Tetrahydroquinoline derivatives as gamma secretase inhibitors
EP1343761B1 (en) Piperidine mch antagonists and their use in the treatment of obesity
EP3183248B1 (en) Tied-back benzamide derivatives as potent rock inhibitors
US6451797B1 (en) Muscarinic antagonists
US6946467B2 (en) Serine protease inhibitors
EP3548468B1 (en) Tricyclic rho kinase inhibitors
CA2538590A1 (en) Novel gamma secretase inhibitors
EP3652165B1 (en) Five membered-aminoheterocyclic and 5,6-or 6,6-membered bicyclic aminoheterocyclic inhibitors of rock for the treatment of heart failure
AU2020286381B2 (en) Imidazolo derivatives, compositions and methods as orexin antagonists
CA3001974A1 (en) 2,4-dihydroxy-nicotinamides as apj agonists
AU2010220561A1 (en) Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
WO2003013527A1 (en) Sulfonamide derivatives as gamma secretase inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued